evipedia.aidev
← Back

Pantothenic Acid for Health & Longevity

Evidence Review created on 08/22/2026 using AI4L / Grok 4

Also known as: Vitamin B5, Pantothenate, Calcium Pantothenate, D-Pantothenic Acid, Dexpanthenol, Panthenol, Pantethine

Motivation

Pantothenic acid, also called vitamin B5, is a water-soluble vitamin the body uses to make coenzyme A, which cells need to turn food into energy. It occurs in nearly all foods—the name comes from a Greek word meaning “from everywhere”—and frank shortage is rare outside severe malnutrition. Longevity-minded adults still meet it as pantethine for serum lipids and as panthenol creams for skin.

Interest grew from mid-century human deprivation experiments that produced fatigue, burning feet, and gastrointestinal symptoms that reversed when the vitamin was restored, and from lipid clinics that used pantethine in the 1980s. Later dermatology work on panthenol creams kept a skin-barrier use in view even though mixed diets usually meet the adult need of about five milligrams a day.

This review examines oral pantothenic acid and its common related forms—calcium pantothenate, pantethine, and topical dexpanthenol—for lipid, skin, and longevity outcomes, together with dose, safety, interactions, and what current trials are testing.

Benefits - Risks - Protocol - Conclusion

High-level overviews of pantothenic acid covering biochemistry, skin use, lipids, and clinical context.

Kresser places pantothenic acid in a food-first skin protocol, covering wound repair, keratinocytes, glutathione, processing losses, and food sources.

The Linus Pauling Institute monograph covers coenzyme A chemistry, adequate intake, wound and lipid data, pantethine, toxicity, and transporter overlap with biotin.

A concise public-health overview of needs, food sources, deficiency signs, high-dose gut effects, and the weak evidence for allergy or arthritis claims.

Narrative review of pantothenic acid in wound repair, immune cytokine switching, and rheumatologic observations, useful for the inflammation angle.

A dedicated lecture on vitamin B5 chemistry, coenzyme A, food forms, and why diet usually meets needs even when pharmacologic doses are discussed.

No dedicated pantothenic acid articles or episodes were found from Peter Attia, Andrew Huberman, Rhonda Patrick, or Lifespan.io. FoundMyFitness notes pantethine in a 2021 Q&A without a standalone episode. Life Extension covers B5 inside broader B-complex and cognitive pieces rather than a dedicated review.

Grokipedia

A structured reference on chemistry, coenzyme A biosynthesis, food sources, adequate intake, deficiency, and the limited evidence for extra benefit above dietary adequacy.

Examine

Examine’s supplement monograph covers coenzyme A biochemistry, adequate intake, the limited extra-dietary signal, pantethine lipids, and safety. It concludes that most people meet needs from food and that extra supplementation shows little promise.

ConsumerLab

Independent label testing of B-vitamin products, including pantothenic acid and pantethine, plus brief clinical notes on arthritis, hair, and dose versus daily value.

Systematic Reviews

Systematic reviews and meta-analyses that evaluate pantothenic acid, dietary vitamin B5, or the topical analog dexpanthenol.

Most metabolomics studies found lower pantothenate or a disturbed coenzyme A pathway in Parkinson disease; two diet papers linked higher intake to lower odds.

Pooled B vitamins associated with lower esophageal cancer odds; the vitamin B5 subgroup was not significant (odds ratio 0.49 (a comparison versus 1.0)).

Thirteen trials, including dexpanthenol, showed no strong evidence that topical agents prevent radiation dermatitis versus usual care.

Calcium pantothenate received only a low-grade (2A) recommendation for premature graying; higher-quality vitamin-deficiency links were to B12, folate, and biotin.

Compares barrier and anti-inflammatory topicals used for diaper dermatitis, including dexpanthenol-containing products, in pediatric skin-barrier care.

No systematic review of pantothenic acid toxicity, high-dose oral safety, or pantethine lipid-lowering was found on PubMed; that principal-risk/lipid-efficacy gap is unrepresented here.

Mechanism of Action

Pantothenic acid is the dietary precursor of coenzyme A (CoA, the cell’s main carrier of acyl groups) and of the 4’-phosphopantetheine arm on acyl-carrier protein. Food CoA is hydrolyzed in the gut to free pantothenate, absorbed in the small intestine mainly through the sodium-dependent multivitamin transporter (SMVT, encoded by SLC5A6; the same carrier that moves biotin and lipoic acid). High oral doses also enter by passive diffusion. Pantothenate kinase (especially mitochondrial PANK2) phosphorylates pantothenate—the committed step—after which cysteine addition, decarboxylation, adenylylation, and 3’-phosphorylation yield CoA.

CoA thioesters (acetyl-CoA, succinyl-CoA, malonyl-CoA, and HMG-CoA (a cholesterol-synthesis intermediate)) drive fatty-acid oxidation, the citric acid cycle, sterol and steroid-hormone synthesis, acetylcholine and heme production, and protein acetylation, including histone marks that affect gene expression. Pantethine, a disulfide dimer of pantetheine, sits closer to CoA on this pathway and is the form studied for serum lipids. Dexpanthenol (D-panthenol), the alcohol analog, is oxidized to pantothenate in skin and mucosa.

Only the D-isomer is active. Free pantothenate is not stored except as CoA and is excreted in urine, largely within 24 hours of a dose. Plasma half-life of the free vitamin is on the order of hours; intracellular CoA pools turn over more slowly. Large pantothenate doses can theoretically compete with biotin at SMVT.

Historical Context & Evolution

Roger J. Williams isolated pantothenic acid in the 1930s and named it from the Greek pantothen (“from everywhere”) because it appeared in nearly every food. Wartime “burning feet” in prisoners responded to pantothenic acid. In the 1950s, Hodges, Bean, and colleagues produced human deficiency with a depleted diet plus the antagonist omega-methylpantothenate, documenting fatigue, paresthesias (tingling or burning sensations), insomnia, and gastrointestinal upset that reversed with repletion.

Animal work tied deficiency to adrenal hemorrhage, poor wound repair, and graying fur. Those findings fed “anti-stress” and gray-hair marketing not confirmed in human trials. Italian and Japanese clinics in the 1980s used pantethine for mixed hyperlipidemia; North American diet-controlled trials in the 2010s, funded by Kyowa Hakko and Daiichi, found smaller reductions in low-density lipoprotein cholesterol (LDL-C). Dexpanthenol ointments (Bepanthen) entered dermatology in the 1940s; Bayer-linked reviews remain a large share of it.

Gardner (1948) reported longer fly life with pantothenic acid in royal jelly, and Pelton and Williams (1958) reported longer mouse survival. Those experiments were not replicated as lifespan studies. Pantothenate kinase–associated neurodegeneration (PKAN), caused by PANK2 mutations, is not dietary B5 deficiency; fosmetpantotenate failed a Phase 3 trial (Klopstock et al., 2021). Current debate centers on brain pantothenate in Parkinson disease, CoA decline with age, and whether extra B5 helps checkpoint immunotherapy or feeds MYC-high (growth-driving gene) tumors.

Expected Benefits

High 🟩 🟩 🟩

Prevention and reversal of pantothenic acid deficiency

Frank deficiency is rare on mixed diets but is a documented human disease state. Experimental deprivation, sometimes with the antagonist omega-methylpantothenate, produced fatigue, burning feet, insomnia, and gastrointestinal symptoms that reversed with repletion (Hodges et al., 1958). The adult adequate intake of 5 mg/day reflects usual intakes in healthy groups, not a trial in already-replete people. Ordinary intake prevents that deficiency; it is not a performance gain above adequacy.

Magnitude: Mixed diets of about 4–7 mg/day meet the adult adequate intake of 5 mg/day; experimental deficiency produced clinical symptoms within weeks of severe restriction.

Medium 🟩 🟩

Topical dexpanthenol for skin-barrier repair

Five percent dexpanthenol creams raise outer-skin (stratum corneum) hydration, cut water loss, and speed epidermal repair (Ebner et al., 2002). Bayer-affiliated authors wrote several widely cited reviews. A systematic review found no clear preventive advantage of topical agents, including dexpanthenol, for radiation skin injury (Ferreira et al., 2017). Oral pantothenate plus vitamin C did not improve surgical tattoo-removal wounds (Vaxman et al., 1995).

Magnitude: Epidermal regeneration accelerated versus vehicle in controlled wound models; the literature reports no single pooled outcome figure, and a radiation-dermatitis systematic review found no strong preventive effect of dexpanthenol.

Pantethine and atherogenic lipids

Pantethine at 600–900 mg/day lowered LDL-C about 4–11% in placebo-controlled trials. Diet-controlled North American randomized trials (n=120 and n=32), supported in part by Kyowa Hakko and Daiichi (Rumberger et al., 2011; Evans et al., 2014), showed smaller effects than 1980s Italian mixed-lipid (type IIb) series (Gaddi et al., 1984). Pantethine is not calcium pantothenate, which has not shown comparable lipid changes. Gastrointestinal symptoms can occur at these doses.

Magnitude: LDL-C fell about 4% versus placebo at 16 weeks in the n=120 trial; the n=32 trial reported an 11% fall from baseline (placebo rose about 3%) at 600–900 mg/day; an older mixed-lipid (type IIb) series reported about 13.5% LDL-C reduction (Gaddi et al., 1984).

Low 🟩

Facial acne lesion reduction at gram doses

A 12-week randomized trial of 2.2 g/day reduced facial lesion count versus placebo (P=0.0197 (the chance-only probability)) in 41 adults (Yang et al., 2014). An earlier uncontrolled series used about 10 g/day (Leung). Larger replications are limited.

Magnitude: The active arm had a greater than 67% reduction in total facial lesions at 12 weeks; the between-group comparison versus placebo was P=0.0197.

Premature hair graying

A systematic review assigned calcium pantothenate only a low-grade (2A) recommendation for premature graying, with stronger deficiency links to B12, folate, and biotin (Mahendiratta et al., 2020). Human reversal data are sparse. Animal fur-graying from deficiency does not establish a cosmetic effect in replete adults.

Magnitude: Grade 2A only; the literature reports no pooled repigmentation figure.

Speculative 🟨

Lifespan extension

Mice given extra pantothenic acid lived longer in a 1958 report, and 1948 fly work treated B5 as a royal-jelly longevity factor. No controlled human study exists; the basis is historical animal work only.

Support of immune checkpoint therapy (drugs that restore T-cell antitumor activity)

Vitamin B5 can favor T-cell function in preclinical immunotherapy models, which motivates a melanoma add-on trial of 2 g/day. Human efficacy is not established; the basis is mechanistic and early-phase only.

Lower pantothenate signal in Parkinson biology

A 2026 systematic review found lower pantothenate in most Parkinson metabolomics studies (Kheirouri & Alizadeh, 2026). This is association, not a supplementation outcome.

Rheumatoid arthritis symptom relief

Older calcium-pantothenate series and later reviews describe lower blood B5 and less morning stiffness in rheumatoid arthritis (Gheita et al., 2020). No modern confirmatory randomized trial exists; the basis is historical and observational only.

Benefit-Modifying Factors

  • PANK2 and related CoA-pathway variants: Biallelic PANK2 mutations cause PKAN by blocking the first step of CoA synthesis. Extra oral B5 does not replace the missing kinase; fosmetpantotenate did not improve function in Phase 3.

  • Baseline intake and blood level: Benefit above deficiency is most plausible when diet is refined, highly processed, or very low in animal foods and whole grains. Replete adults on mixed diets already meet the 5 mg adequate intake.

  • Sex: Adequate intake is 5 mg/day for both adult sexes; it rises to 6 mg in pregnancy and 7 mg in lactation. Lipid and acne trials enrolled mixed sexes without a consistent sex split.

  • Pre-existing dyslipidemia and inflammatory skin disease: Pantethine lipid effects were studied in hyperlipidemia; topical dexpanthenol was studied in irritation, wounds, and barrier defects, not as a systemic longevity drug.

  • Age: The adequate intake does not rise after 50 years. Older adults remain the group in whom processed-food diets and low energy intake can still leave gaps, without evidence that megadoses add years.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Watery diarrhea and gastrointestinal upset

The National Academy of Medicine set no tolerable upper intake level because usual intakes have not produced a clear toxic syndrome. Its members do not derive product or clinic revenue from that conclusion. Diarrhea, and sometimes nausea, occurs at about 10–20 g/day of calcium D-pantothenate; water-soluble vitamin overdose reviews list diarrhea among nonspecific toxicities (Chawla & Kvarnberg, 2014). Pantethine lipid protocols at 600–1,200 mg/day more often cause nausea and heartburn than watery diarrhea.

Magnitude: Diarrhea is reported at approximately 10–20 g/day of calcium D-pantothenate; nausea and heartburn are reported at 600–1,200 mg/day of pantethine; no tolerable upper intake level has been set.

Medium 🟥 🟥

Allergic contact dermatitis from topical dexpanthenol

Leave-on 5% dexpanthenol products are widely used and usually well tolerated. Dermatology series document allergic contact dermatitis, irritation, and eczema from panthenol ointments and cosmetics (Ebner et al., 2002). Sensitization is uncommon relative to use volume but is a documented, reversible, skin-limited risk. Oral B5 does not produce this contact pattern.

Magnitude: Several published case series document panthenol contact allergy; large incidence figures are not reported relative to total cosmetic use.

Low 🟥

Eosinophilic pleuropericardial effusion (with biotin)

An elderly woman developed eosinophilic pleurisy (lung-lining white-cell inflammation) and pericardial tamponade (heart-sac pressure) after two months on 300 mg/day pantothenic acid, 10 mg/day biotin (Debourdeau et al., 2001). Recovery followed withdrawal. B5 and biotin cannot be separated.

Magnitude: One published case after 300 mg/day pantothenic acid plus 10 mg/day biotin for two months; no incidence rate exists.

Speculative 🟨

Fueling MYC-high tumor coenzyme A metabolism

In mammary tumors, pantothenic acid clustered in MYC-high regions, where MYC upregulates SMVT and CoA flux. Dietary B5 restriction slowed tumor growth in that model. This is animal work, not a human harm signal.

Competition with biotin at SMVT

Pantothenate, biotin, and lipoic acid share SMVT. Very large B5 doses could, in principle, reduce biotin uptake. Clinical biotin deficiency from B5 supplements has not been shown; the basis is transporter biochemistry.

Risk-Modifying Factors

  • SMVT/SLC5A6 overlap: High pantothenate and high biotin share one transporter. Combined megadoses were the setting of the eosinophilic effusion case and are the theoretical biotin-competition setting.

  • Baseline gut function: Multi-gram loads are more likely to cause diarrhea in people with irritable bowel, short gut, or recent antibiotics; dietary milligram doses are not.

  • Baseline blood and urine pantothenate: Megadose diarrhea is driven by oral load, not by a low starting blood or urine B5 value; replete adults still get gastrointestinal upset at 10–20 g/day.

  • Sex: No consistent sex difference in B5 adverse events is described. Pregnancy raises the adequate intake to 6 mg; megadose acne protocols are not characterized in pregnancy.

  • Pre-existing atopy (allergic tendency) and damaged barrier: Prior contact allergy or active eczema raises the chance that dexpanthenol cream will irritate rather than soothe.

  • Age and comorbidity: The effusion case was elderly. MYC-high breast tumor biology is a theoretical concern in active cancer, not a demonstrated risk of a standard multivitamin.

Key Interactions & Contraindications

  • Statins and niacin (caution, additive lipids): Pantethine plus statins (cholesterol-lowering drugs such as atorvastatin or rosuvastatin) or nicotinic acid may lower LDL-C further; lipid and symptom monitoring is the usual mitigator.

  • Oral contraceptives (caution, higher requirement): Estrogen–progestin oral contraceptives may increase pantothenic acid requirement; dietary adequacy or a standard multivitamin is the usual response, not megadosing.

  • Tetracycline antibiotics (caution, absorption): Concurrent minerals and some B vitamins can blunt tetracycline (doxycycline, minocycline) absorption; separating doses by several hours is the usual mitigator.

  • Cholinesterase inhibitors (monitor, theoretical cholinergic additivity): Drugs that slow acetylcholine breakdown (donepezil, rivastigmine) plus high-dose B5 are a caution for excess cholinergic effects, not an established interaction.

  • Biotin and lipoic acid (caution, shared SMVT): Large co-administration can compete at SMVT; the effusion case used B5 plus biotin. Staggering high doses is a reasonable mitigator.

  • Other B-complex products (caution, hidden B6): High-dose B5 combination products often contain pyridoxine well above the B6 upper limit and can cause neuropathy that is then blamed on B5.

  • Over-the-counter products (none established): No specific OTC drug interaction is documented for pantothenic acid; the practical caution is hidden B6 in OTC B-complex products rather than a named OTC medicine.

Populations who should avoid Pantothenic Acid:

  • Known allergy to dexpanthenol, panthenol, or calcium pantothenate (absolute for that form)
  • Unexplained eosinophilia or recent unexplained pleural or pericardial effusion while using high-dose B5 plus biotin (caution until evaluated)
  • None identified for food-level or 5 mg adequate-intake amounts, including pregnancy at the 6–7 mg adequate-intake level

Risk Mitigation Strategies

  • Stay below the diarrhea threshold: Published protocols keep oral calcium pantothenate well under 10 g/day and split gram doses with food, avoiding osmotic diarrhea documented at 10–20 g/day.

  • Split pantethine and take with meals: 300 mg two or three times daily with food lowers the chance of nausea and heartburn reported at 600–1,200 mg/day.

  • Patch-test dexpanthenol: A 24–48 hour trial on a small skin area before wide use reduces the chance of missing contact allergy.

  • Avoid paired megadose B5 and biotin: The 300 mg B5 plus 10 mg biotin pattern used in the effusion case is the combination that report implicates.

  • Read the full B-complex label: High-dose combination products often include pyridoxine in the neuropathy range, which can be mistaken for a B5 effect.

  • Active MYC-driven cancer: In that setting, extra pharmacologic B5 is a theoretical metabolic fuel; published work uses dietary adequacy without megadosing as the conservative stance.

Therapeutic Protocol

  • Dietary baseline: Adult adequate intake is 5 mg/day (6 mg pregnancy, 7 mg lactation), typically met by liver, eggs, mushrooms, avocado, yogurt, and whole grains, or by a multivitamin at 100% Daily Value.

  • Pantethine lipid protocol: After 1980s Italian clinic use, Kyowa-supported North American randomized controlled trials (RCTs) used 600 then 900 mg/day for 8 weeks each, in divided doses with a lipid-lowering diet.

  • Acne protocols in the literature: Yang et al. used 2.2 g/day in divided doses with food for 12 weeks; Leung described about 10 g/day. These are not dietary-adequacy regimens.

  • Topical dexpanthenol: Leave-on 5% cream or ointment (Bepanthen-type products used in dermatology since the 1940s), often twice daily on intact or superficially injured skin.

  • Timing: Water-soluble B5 has a short plasma half-life (hours). Milligram doses are typically taken once in the morning; gram doses and pantethine are split two to three times daily with meals.

  • PANK2 / PKAN: High-dose pantothenate and pantethine have been tried as n-of-1 (single-patient) adjuncts; fosmetpantotenate 300 mg three times daily did not beat placebo in Phase 3.

  • Sex and life stage: No sex-specific dose is established beyond pregnancy and lactation adequate intakes. Acne megadose data are not pregnancy-tested.

  • Age: The adequate intake is unchanged after 50 years; older adults more often use a multivitamin than a gram-dose B5 product.

  • Baseline lipids and diet: Pantethine was studied on top of therapeutic lifestyle change; starting lipids and apoB (apolipoprotein B, the particle-number marker) shape whether a 4–11% LDL-C change is meaningful.

  • Malabsorption and inflammatory bowel disease (IBD): Short-gut states can lower water-soluble vitamin uptake; one IBD trial used 60 mg/day, not grams.

Discontinuation & Cycling

  • Duration: Dietary adequacy is ongoing. Pantethine lipid trials lasted 16 weeks. Acne RCTs lasted 12 weeks. Topical dexpanthenol is used while the barrier defect lasts.

  • Withdrawal: No pantothenic acid withdrawal syndrome is described; excess is excreted in urine. Stopping megadoses typically ends diarrhea within days.

  • Taper: Tapering is not required for physiologic or pantethine doses. People using >2 g/day sometimes step down to reduce rebound loose stools, without a formal taper trial.

  • Cycling: No cycling protocol is established to “preserve efficacy.” CoA pools are maintained by regular intake, not by on/off blocks.

Sourcing and Quality

  • Form: Labels list calcium D-pantothenate (stable salt), D-pantothenic acid, dexpanthenol/panthenol (topical or oral alcohol analog), or pantethine (disulfide used for lipids). Only the D-isomer is active.

  • What to look for: Third-party testing (USP, United States Pharmacopeia; NSF International; or ConsumerLab) for identity and milligram amount; many B-complex products far exceed the 5 mg adequate intake.

  • Pantethine identity: Pantesin-style pantethine is a different molecule from calcium pantothenate; lipid trial doses are 600–900 mg pantethine, not 5–10 mg B5.

  • Brands: ConsumerLab has tested standalone pantothenic acid (including Jarrow) and pantethine products inside its B-vitamin review; compounding is not required for these forms.

  • Stability: Calcium pantothenate is preferred in capsules because free acid is hygroscopic. Heat, canning, and milling can cut food B5 by more than half.

Practical Considerations

  • Time to effect: Deficiency symptoms reverse over days to weeks after repletion. Pantethine lipid changes appeared by 4–8 weeks. Acne lesion counts were compared at 12 weeks. Topical barrier effects can appear within days.

  • Common pitfalls: Treating a B-complex neuropathy as “B5 toxicity”; using 10 g/day for acne without expecting diarrhea; assuming pantethine results apply to a 10 mg multivitamin; expecting oral B5 to heal surgical wounds.

  • Regulatory status: In the United States, oral products are dietary supplements, not approved drugs for lipids, acne, or longevity. Dexpanthenol ointments are cosmetics or over-the-counter skin protectants. Pantethine is a U.S. supplement and has been used as a lipid agent in Japan.

  • Cost and access: Calcium pantothenate is inexpensive. Pantethine costs more per milligram but far less than prescription lipid drugs; insurers typically cover statins, not pantethine, which can bias guidelines and trial funding.

Interaction with Foundational Habits

  • Sleep: Direct. Experimental deficiency produced insomnia; repletion removed it. Pharmacologic B5 is not a documented sleep aid in replete adults, so evening gram doses add no proven sleep benefit and may add nocturia (nighttime urination) from fluid with large tablet loads.

  • Nutrition: Direct. Refined grains, canning, and boiling leach B5; liver, eggs, mushrooms, yogurt, and avocado supply it. A mixed whole-food diet usually hits 5 mg without a standalone product. Pantethine lipid trials kept a background therapeutic diet.

  • Exercise: None shown. Seven days of pantethine/pantothenate plus allithiamin did not change 50 km cycling metabolism or a 2,000 m time trial versus placebo in trained cyclists (Webster, 1998).

  • Stress management: Indirect and weak. Animal deficiency injures the adrenal cortex, which spawned “anti-stress vitamin” claims. Human evidence is limited to deficiency symptoms, not cortisol optimization in replete adults.

Monitoring Protocol & Defining Success

Before starting a standalone pantothenic acid or pantethine product, a useful baseline is a diet recall (processed versus whole-food B5 sources), a lipid panel with apoB if the goal is lipids, and, for gram-dose acne protocols, a complete blood count and hepatic panel as used in the 12-week RCT. Routine blood pantothenate is optional; urinary excretion above 1 mg/day is the adequacy marker used when the adequate intake was set. Whole-blood pantothenate, when available, is more stable than plasma.

For pantethine, lipids and apoB at 8 and 16 weeks match the trial schedule, then every 6–12 months if continued. Gram-dose acne protocols can repeat lesion counts and safety labs at 12 weeks. Dietary-adequacy use does not require recurring B5 blood tests; a yearly multi-ingredient panel is enough for most longevity clinics. Qualitative markers are checked continuously.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Urinary pantothenic acid >1 mg/day Adequacy marker used for the adult adequate intake 24-hour collection; not a longevity “optimize upward” target
Whole-blood pantothenate 1.6–2.7 µmol/L Reflects circulating vitamin better than a single plasma draw Conventional plasma ranges vary by lab (~0.2–1.8 µmol/L); fasting not required
LDL-C (if using pantethine) Often <70–100 mg/dL in prevention clinics Tracks the modest LDL-C effect of pantethine Conventional <100–130 mg/dL by risk category; pair with apoB
apoB (if using pantethine) Often <80–90 mg/dL in prevention clinics Particle number, more informative than LDL-C alone Fasting preferred; 4–8 and 16 week checks match trial timing
CBC and hepatic panel (gram-dose protocols) No established target; track stability versus the person’s own baseline Safety labs used in the 2.2 g/day acne RCT CBC is complete blood count; not needed for 5 mg adequate-intake or standard multivitamin use

Qualitative markers:

  • Resolution of burning feet, paresthesias, unexplained fatigue, or insomnia if those began in a low-intake setting
  • Skin-barrier comfort and wound appearance with topical dexpanthenol
  • Facial inflammatory lesion count if a gram-dose acne protocol is used
  • Stool frequency and cramping after any dose increase
  • No new dyspnea (shortness of breath), chest pain, or rash after high-dose B5 plus biotin

Emerging Research

  • PANTHEON-IO melanoma trial: NCT06377111 is a Phase 1, n=12 study of 2,000 mg/day calcium pantothenate with nivolumab plus ipilimumab in unresectable melanoma, testing a ≥50% plasma B5 rise by week 9 and colitis/microbiome signals (active, not recruiting).

  • IBD adjunct trial: NCT05701501 randomized ~100 adults with inflammatory bowel disease to vitamin B5 60 mg/day versus placebo for 12 weeks on standard therapy; status is unknown, with no posted results.

  • Failed PKAN replacement: Fosmetpantotenate 300 mg three times daily did not improve PKAN-ADL (a disease-specific daily-function score) versus placebo in 84 patients (Klopstock et al., 2021; NCT03041116), weakening the idea that downstream CoA analogs rescue PANK2 disease.

  • Parkinson metabolomics: Kheirouri & Alizadeh, 2026 synthesize consistent pantothenate depletion in Parkinson biosamples; a supplementation RCT that could confirm or refute a causal role has not been done.

  • MYC-high tumors versus immunotherapy: Kreuzaler et al., 2023 show B5 feeding MYC-driven mammary tumor CoA flux, while Bourgin, Kepp & Kroemer, 2022 argue B5 can aid checkpoint immunotherapy—opposite implications for extra intake in cancer.

  • Aging CoA pools: Liu et al., 2025 link age-associated CoA decline to intestinal stem-cell dysfunction in animals, a mechanistic aging lead that human dosing studies have not tested.

Conclusion

Pantothenic acid is the vitamin used to make coenzyme A, and that job is not in dispute. On ordinary mixed diets the adult need is about five milligrams a day. What is in dispute is whether gram doses, pantethine, or panthenol creams add healthy years on top of adequacy.

The strongest extra-dietary signals are modest and form-specific. Pantethine, a related molecule, lowered artery-clogging lipid particles in diet-controlled trials that industry helped fund, less than modern lipid drugs. Panthenol creams can help a damaged skin barrier versus the cream base, while independent radiation-skin reviews found no clear preventive effect. Gram-dose acne data rest on one small randomized study. Parkinson and aging papers describe low pantothenate in tissue; they do not show that extra oral doses change disease course.

Harm is limited but not imaginary. Multi-gram calcium pantothenate causes diarrhea. Panthenol cosmetics can trigger contact allergy. One elderly patient developed a life-threatening fluid buildup around the lungs and heart on pantothenic acid plus biotin. Tumor work raises a theoretical concern that extra pantothenic acid can feed some growth programs.

For a risk-aware adult on mixed diets, the evidence describes a low-cost nutrient at dietary doses, a modest lipid tool only in the pantethine form, and a topical barrier agent—not a general longevity intervention. Industry-funded lipid and ointment papers sit beside a no-upper-limit call from the National Academy of Medicine, whose members do not sell this vitamin. Insurers typically cover statins, not pantethine, which can bias lipid guidelines and trial funding.

Top - Benefits - Risks - Protocol